"Phenols" - Books

Result Filters

Results: 1 to 20 of 261 books (2999 items)

<< First< Prev

Page of 14

Next >Last >>

Select item 32236521.

Toxicological Risks of Selected Flame-Retardant Chemicals.

National Research Council (US) Subcommittee on Flame-Retardant Chemicals.

Washington (DC): National Academies Press (US); 2000.

Top results in this book Table of Contents

Select item 47929722.

Pentachlorophenol and Some Related Compounds.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.

Lyon (FR): International Agency for Research on Cancer; 2019. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 117.)

Top results in this book Table of Contents

Select item 50553123.

NTP Technical Report on the Toxicology Studies of a Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] (CASRN 32534-81-9) in F344/N Rats and B6C3F1/N Mice and Toxicology and Carcinogenesis Studies of a Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] in Wistar Han [Crl:WI(Han)] Rats and B6C3F1/N Mice (Gavage Studies): Technical Report 589 [Internet].

National Toxicology Program.

Research Triangle Park (NC): National Toxicology Program; 2016 Feb.

Top results in this book Table of Contents

Select item 47970064.

NTP Research Report on the CLARITY-BPA Core Study: A Perinatal and Chronic Extended-Dose-Range Study of Bisphenol A in Rats: Research Report 9 [Internet].

National Toxicology Program.

Research Triangle Park (NC): National Toxicology Program; 2018 Sep.

Top results in this book Table of Contents

Select item 42174905.

Ivacaftor (Kalydeco) 150 mg Tablet: For Treatment of Cystic Fibrosis with G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or G970R Mutation [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.

Top results in this book Table of Contents

Select item 47602166.

Clinical Review Report: Lumacaftor/Ivacaftor (Orkambi): (Vertex Pharmaceuticals (Canada) Incorporated): Indication: For the treatment of cystic fibrosis in patients aged six years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.

Top results in this book Table of Contents

Select item 47594287.

Clinical Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.

Top results in this book Table of Contents

Select item 44957348.

5-Fluorouracil 0.5% and Salicylic Acid 10.0% (Actikerall) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.

Top results in this book Table of Contents

Select item 32338929.

Health Effects of Permethrin-Impregnated Army Battle-Dress Uniforms.

National Research Council (US) Subcommittee to Review Permethrin Toxicity from Military Uniforms.

Washington (DC): National Academies Press (US); 1994.

Top results in this book Table of Contents

Select item 474912210.

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep.

Top results in this book Table of Contents

Select item 434989611.

Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.

Lyon (FR): International Agency for Research on Cancer; 2000. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 76.)

Top results in this book Table of Contents

Select item 412795612.

Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Whitlock EP, Williams SB, Burda BU, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 132.)

Top results in this book Table of Contents

Select item 491429013.

NTP Technical Report on the Toxicity Studies of 5-Amino-o-cresol (CASRN 2835-95-2) Administered Dermally to F344/NTac Rats and B6C3F1/N Mice: Toxicity Report 89 [Internet].

National Toxicology Program.

Research Triangle Park (NC): National Toxicology Program; 2015 Nov.

Top results in this book Table of Contents

Select item 474505814.

Clinical Review Report: Ticagrelor (Brilinta) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.

Top results in this book Table of Contents

Select item 477854015.

Clinical Review Report: Rivaroxaban (Xarelto): Bayer Inc. Indication: In combination with 75 mg to 100 mg acetylsalicylic acid, for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease with or without peripheral artery disease [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jan.

Top results in this book Table of Contents

Select item 475924816.

Pharmacoeconomic Review Report: Lumacaftor/Ivacaftor (Orkambi): (Vertex Pharmaceuticals (Canada) Incorporated): Indication: For the treatment of cystic fibrosis in patients 6 years of age and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.

Top results in this book Table of Contents

Select item 458459417.

Comparing Antithrombotic Strategies after Bioprosthetic Aortic Valve Replacement: A Systematic Review [Internet].

Papak J, Chiovaro J, Noelck N, et al.

Washington (DC): Department of Veterans Affairs (US); 2017 Dec.

Top results in this book Table of Contents

Select item 254698818.

Neural Control of Renal Function.

Kopp UC.

San Rafael (CA): Morgan & Claypool Life Sciences; 2011.

Top results in this book Table of Contents

Select item 306685819.

Evaluation of the Benefits and Harms of Aspirin for Primary Prevention of Cardiovascular Events: A Comparison of Quantitative Approaches [Internet].

Puhan MA, Singh S, Weiss CO, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov.

Top results in this book Table of Contents

Select item 475934620.

Pharmacoeconomic Review Report: Tapentadol Hydrochloride Extended-Release Tablet (Nucynta Extended-Release): (Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.

Top results in this book Table of Contents

<< First< Prev

Page of 14

Next >Last >>

Supplemental Content

Images search in Bookshelf

Figure 3-1Mammalian Metabolism of Chlorobenzene to Phenols, Dihydrodiols, Catechols, and Glutathione Conjugates

TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.

Toxicological Profile for Chlorobenzene. Atlanta (GA): Agency for Toxic Substances and Disease Registry (US); 2020 Oct.
Figure 12.2

Metabolic activation of benzo[a]pyrene. (1) Cytochrome P-450 (CYP1A1) catalyzes initial epoxidation across the 1 - 2, 2 - 3, 4 - 5, 7 - 8 (shown), 9 - 10 and 11 - 12 positions. (2) With the exception of the 1 - 2 and 2 - 3 oxides which convert to phenols, epoxide hydrolase catalyzes the formation of dihydrodiols. (3) Benzo[a]pyrene-7, 8-dihydrodiol is further metabolized at the olefinic double bond by cytochrome P450 (CYP1A1 and CYP3A4) to form a vicinal diol-epoxide (r7, t8-dihydroxy-c9, 10 epoxy-7,8,9,10-tetrahydroxybenzo[a]pyrene). (4) The highly unstable arene ring opens spontaneously to form a carbocation. (5) This electrophic species forms a covalent bond between the 10 position of the hydrocarbon and the exocylic amino group of deoxyguanosine.

Chemical Carcinogenesis.

Bast RC Jr, Kufe DW, Pollock RE, et al., editors. Holland-Frei Cancer Medicine. 5th edition. Hamilton (ON): BC Decker; 2000.
Figure 17-3

Metabolic activation of benzol[α]pyrene. (1) Cytochrome P450 (CYP1A1) catalyses initial epoxidation across the 1 - 2, 2 - 3, 4 - 5, 7 - 8 (shown), 9 - 10 and 11 - 12 positions. (2) With the exception of the 1 - 2 and 2 - 3 oxides that convert to phenols, epoxide hydrolase may catalyze the formation of dihydrodiols. (3) Benzo[a]pyrene-7, 8-dihydrodiol is further metabolized at the olefinic double bond by cytochrome P450 (CYP1B1 and CYP3A4) to form a vicinal diol-epoxide (r7, t8-dihydroxy-c9, 10 epoxy-7,8,9,10-tetrahydroxybenzo[a]pyrene). (4) The highly unstable arene ring opens spontaneously to form a carbocation. (5) This electrophic species forms a covalent bond between the 10 position of the hydrocarbon and the exocyclic amino group of deoxyguanosine.

Carcinogen Metabolism.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.